文献速递牙体牙髓病

可注射可回收的温敏水凝胶药物递送系统用于牙髓治疗

An Innovative Injectable and Retrievable Drug Delivery System for Endodontic Therapy.
PubMed 文献 · J Endod · 2025-08-14

本研究将水杨酸钙(CASA)封装于光交联温敏F127-DMA水凝胶,评估其可注射性、可回收性、抗粪肠球菌生物膜效果及细胞毒性。结果显示F127-DMA/CASA黏度较糊剂降低三个数量级,回收后残留药物约6%显著低于Vista-Cal的26%,20% CASA处理21天生物膜后CFU减少6-log并完全清除生物膜,牙髓干细胞倍增时间无显著变化。

要点

  • F127-DMA/CASA黏度较糊剂降低三个数量级,便于注射和回收。
  • 回收后残留药物约6%,显著低于Vista-Cal的26%。
  • 20% CASA处理21天粪肠球菌生物膜后CFU减少6-log并完全清除。

核心结论

  • F127-DMA/CASA具有优越的流动性、可回收性、近中性pH(约6)、生物相容性和抗粪肠球菌效能,有望优于氢氧化钙作为根管内封药。

研究设计与样本

  • CASA由氢氧化钙与水杨酸按1:6比例混合制备,并以不同浓度掺入F127-DMA,使用苯基(2,4,6-三甲基苯甲酰基)膦酸锂进行光交联。
  • 采用塑料根管训练块、牛牙锥形束CT扫描和振荡流变学评估可注射性与可回收性。
  • 在牛离体牙上接种粪肠球菌生物膜后注射化合物,评估体外抗菌效能;使用牙髓干细胞测量细胞毒性。

主要发现

  • 封装CASA于F127-DMA使黏度较糊剂降低三个数量级,便于注射和回收。
  • 回收后F127-DMA/CASA残留药物约6%,Vista-Cal为26%。
  • X射线衍射、拉曼和傅里叶变换红外光谱分析证实CASA形成并成功整合入光交联F127-DMA。
  • 粪肠球菌接种21天后,F127-DMA/20% CASA处理使CFU减少6-log并完全清除生物膜。
  • 处理后的牙髓干细胞倍增时间无显著变化。

关键数值与推荐

  • CASA由氢氧化钙与水杨酸按1:6比例混合制备。
  • F127-DMA/CASA回收后残留药物约6%,Vista-Cal为26%。
  • F127-DMA/20% CASA处理21天粪肠球菌生物膜后CFU减少6-log并完全清除生物膜。
  • F127-DMA/CASA pH近中性(约6)。

临床怎么用

  • 该材料可注射且可回收,残留药物低,可能改善根管内封药的放置与去除。
  • 对粪肠球菌生物膜显示高效清除,且对牙髓干细胞倍增时间无显著影响,提示生物相容性较好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Endodontic treatment failures remain a significant treatment challenge. Different bacterial combinations are implicated in posttreatment disease. Enterococcus faecalis is often detected in these biofilms. Calcium hydroxide has many limitations, including low flowability, difficult retrieval, high pH, and limited efficacy against E. faecalis. Here, we show that these difficulties can be overcome using calcium salicylate (CASA) encapsulated in a photocrosslinked thermoreversible F127-dimethacrylamide (DMA) hydrogel. METHODS: CASA was prepared by mixing calcium hydroxide and salicylic acid in a 1:6 ratio, respectively and incorporated into F127-DMA at different concentrations. The mixture was photocrosslinked using lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate. Chemical properties were analyzed using X-ray diffraction, Raman spectroscopy, Fourier transform infrared spectroscopy, and differential scanning calorimetry, while injectability and retrievability were assessed using plastic root canal training blocks, bovine teeth cone beam computed tomography scans, and oscillatory rheology. In Vitro antibacterial efficacy against E. faecalis biofilm was probed by injection of the compound, following inoculation on bovine extracted teeth. Cytotoxicity of the compound was measured using dental pulp stem cells. RESULTS: Encapsulation of CASA in F127-DMA reduced the viscosity by three orders of magnitude compared to the paste form, facilitating injection and enabling retrieval. Following retrieval, F127-DMA/CASA showed significantly lower residual medicament (∼6%) compared to Vista-Cal (26%). X-ray diffraction, Raman, and Fourier transform infrared spectroscopy analyses confirmed the formation of CASA and successful integration of CASA into photocrosslinked F127-DMA. Treatment with the F127-DMA/20% CASA following 21-day inoculation with E. faecalis resulted in a 6-log reduction in CFU and complete elimination of biofilm. No significant change in the doubling time of treated dental pulp stem cell was observed. CONCLUSIONS: F127-DMA/CASA exhibits superior flowability, retrievability, near-neutral pH (∼6), biocompatibility, and anti-E. faecalis efficacy, which highlights its potential as a significant improvement over calcium hydroxide as an endodontic intracanal medicament.

来源:J Endod,查看原文。版权归原作者所有。

引用

  1. Mahmoud AH, Sloutski A, Fu S, et al. An Innovative Injectable and Retrievable Drug Delivery System for Endodontic Therapy. J Endod. 2025. PMID: 40816576. doi:10.1016/j.joen.2025.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。